|
|
 |
|
Viewing report
|
|
|
|
Summary: BioMed Realty Trust Inc. Jun 11
Standard & Poors, June 2011
Abstract
Our ratings on San Diego, Calif.-based BioMed Realty Trust Inc. reflect the company's satisfactory business risk profile as characterized by good internal cash flow growth prospects from a portfolio of office and laboratory properties serving the life science industry. Internal growth plus recent accretive acquisitions have bolstered coverage measures that now better support our intermediate financial risk assessment. BioMed is a moderate-size REIT with a $3.9 billion real estate portfolio that aggregates more than 12 million square feet, including 1.5 million square feet acquired in 2010. The properties are geographically concentrated in a small number of biotech and pharmaceutical markets, particularly Boston (34% of rent) and San Francisco (16% of rent). The properties are also leased to a concentrated tenant...
Companies mentioned in this report are: BioMed Realty Trust Inc.
Action: Review
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
This product consists of a Summary Analysis: Bi-annual (at least). An abbreviated analysis containing Standard & Poor's issuer credit ratings as of the time the article was published. The analysis includes a rating rationale - the basis on which the rating was assigned - and an outlook section if the issuer is not on CreditWatch. Financial statistics are not included.
|
|
|
|
